Is there a Role for Sodium Orthovanadate in the Treatment of Diabetes?

Deepthi B, Sowjanya K, Lidiya B, Bhargavi RS, Babu PS. A modern review of diabetes mellitus: an annihilatory metabolic disorder.

Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-a devastating metabolic disorder.

Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic complications of diabetes mellitus: A mini review.

Forouhi NG, Wareham NJ. Epidemiology of diabetes.

Himaja J, Suresha BS, Daniel NG, Kurian L. Assessment of prevalence and drug prescribing pattern of type-II diabetes mellitus 2016; 5(8): 1528-41.

Bhowmick A, Banu S. Therapeutic targets of type 2 diabetes: an overview.

Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.

Dujic T, Causevic A, Bego T, et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med 2016; 33(4): 511-4.

Vieira MNe, Silva NM, Ferreira ST, De Felice FG. Protein tyrosine phosphatase 1B (PTP1B): A potential target for Alzheimer’s therapy?

Jeon YM, Lee S, Kim S. Neuroprotective effects of protein tyrosine phosphatase 1B inhibition against ER stress-induced toxicity.

Thiebaut PA, Besnier M, Gomez E, Richard V. Role of protein tyrosine phosphatase 1B in cardiovascular diseases.

Tonks NK, Diltz CD, Fischer EH. Purification of the major protein-tyrosine-phosphatases of human placenta.

Krishnan N, Konidaris KF, Gasser G, Tonks NK. A potent, selective and orally bioavailable inhibitor of the protein tyrosine phosphatase PTP1B improves insulin and leptin signalling in animal models.

Bakke J, Haj FG. Protein-tyrosine phosphatase 1B substrates and metabolic regulation.

Herre DJ, Norman JB, Anderson R, Tremblay ML, Huby AC, De Chantemèle EJ. Deletion of protein tyrosine phosphatase 1B (PTP1B) enhances endothelial cyclooxygenase 2 expression and protects mice from type 1 diabetes-induced endothelial dysfunction.

Sun W, Zhang B, Zheng H. Trivaric acid, a new inhibitor of PTP1b with potent beneficial effect on diabetes.

Tamrakar AK, Maurya CK, Rai AK. PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011–2014).

Warren EB, Sillivan SE, Konradi C. Receptors and Second Messengers in the Basal Ganglia.

White MF.

Anderie I, Schulz I, Schmid A. Direct interaction between ER membrane-bound PTP1B and its plasma membrane-anchored targets.

Khalil AA, Jameson MJ. Sodium orthovanadate inhibits proliferation and triggers apoptosis in oral squamous cell carcinoma in vitro.

Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats.

Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action.

Brichard SM, Desbuquois B, Girard J. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2.

Bendayan M, Gingras D. Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats.

Blondel O, Simon J, Chevalier B, Portha B. Impaired insulin action but normal insulin receptor activity in diabetic rat liver: Effect of vanadate.

Goldfine AB, Simonson DC, Folli FR, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus and studies.

Gupta BL, Preet A, Baquer NZ. Protective effects of sodium orthovanadate in diabetic reticulocytes and ageing red blood cells of Wistar rats.

Yadav UC, Moorthy K, Baquer NZ. Effects of sodium-orthovanadate and Trigonellafoenum-graecum seeds on hepatic and renal lipogenic enzymes and lipid profile during alloxan diabetes.

Kumar P, Taha A, Kumar N, Kumar V, Baquer NZ. Sodium orthovanadate and prevents neuronal parameters decline and impaired glucose homeostasis in alloxan diabetic rats.

Domingo JL, Gómez M. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research.

Jiang P, Dong Z, Ma B, Ni Z, Duan H, Li X. Effect of vanadyl rosiglitazone, a new insulin-mimetic vanadium complexes, on glucose homeostasis of diabetic mice.

Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation.

Zaporowska H, Wasilewski W. Some selected haematological indices in Wistar rats in the vanadium-ethanol interaction.

Zaporowska H, Wasilewski W. Haematological results of vanadium intoxication in Wistar rats.

Sanchez DJ, Colomina MT, Domingo JL. Effects of vanadium on activity and learning in rats.

De la Torre A, Granero S, Mayayo E, Corbella J, Domingo JL. Effect of age on vanadium nephrotoxicity in rats.

Zwolak I. Vanadium carcinogenic, immunotoxic and neurotoxic effects: a review of in vitro studies.

Sakurai H. Vanadium distribution in rats and DNA cleavage by vanadyl complex: implication for vanadium toxicity and biological effects.

Thompson KH, Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I.

Akesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File for Chapter 7 Bankruptcy, January 21, 2009. Akesis Pharmaceuticals Inc. available at: http://wwwevaluategroup.com/Universal/ View.aspx?type1/4Story&id1/4179437

Jacques-Camarena O, Gonzalez-Ortiz M, Martínez-Abundis EL, Madrueno JF, Medina-Santillan R. Effect of vanadium on insulin sensitivity in patients with impaired glucose tolerance.

Soveid M, Dehghani GA, Omrani GR. Long- term efficacy and safety of vanadium in the treatment of type 1 diabetes.